{"id":32316,"date":"2025-07-22T14:46:56","date_gmt":"2025-07-22T14:46:56","guid":{"rendered":"http:\/\/medexperts.pro\/?p=32316"},"modified":"2025-07-22T15:27:44","modified_gmt":"2025-07-22T15:27:44","slug":"astrazeneca-joins-pharma-investment-push-in-u-s-amid-tariff-threat","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=32316","title":{"rendered":"AstraZeneca Joins Pharma Investment Push in U.S. Amid Tariff Threat"},"content":{"rendered":"
<\/div>\n

The British drug maker plans to invest $50 billion in the United States as it seeks to appease President Trump.<\/p>\n

\n
\n
\n

The British-Swedish drugmaker AstraZeneca has promised to invest $50 billion in the United States by 2030, the latest in a string of pledges by pharmaceutical companies as they try to fend off President Trump\u2019s threat to impose a 200 percent tariff on imported drugs.<\/p>\n

Pascal Soriot, the chief executive of AstraZeneca, announced the plans on Monday in Washington while seated next to Kevin Hassett, the director of the U.S. National Economic Council, and Glenn Youngkin, the governor of Virginia, where the company will direct a major plank of the investment.<\/p>\n

The plans \u201cunderpins our belief in America\u2019s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally,\u201d Mr. Soriot said.<\/p>\n

The investment will go to projects like building a manufacturing plant in Virginia to make drug substances, including for the company\u2019s weight loss drugs. The plant in Virginia will be AstraZeneca\u2019s largest single manufacturing investment in its 26-year history, the company said. The money will also go toward plants in California, Indiana, Maryland and Texas, as well as expanding research and development facilities in Maryland and Massachusetts.<\/p>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n

\u201cFor decades, Americans have been reliant on foreign supply of key pharmaceutical products,\u201d Howard Lutnick, the U.S. commerce secretary, said in a statement as part of the AstraZeneca announcement. \u201cPresident Trump and our nation\u2019s new tariff policies are focused on ending this structural weakness.\u201d<\/p>\n

This year, some of the world\u2019s largest pharmaceutical companies have announced billions in investments in the United States. Roche, the Swiss company, said in April it would put $50 billion into research and development centers and manufacturing sites. Novartis, another Swiss firm, said it would invest $23 billion over the next five years. American companies including Johnson & Johnson, Eli Lilly and AbbVie have also announced major investments.<\/p>\n

\n
\n
<\/div>\n
\n
\n
\n

We are having trouble retrieving the article content.<\/p>\n

Please enable JavaScript in your browser settings.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into<\/a>\u00a0your Times account, or\u00a0subscribe<\/a>\u00a0for all of The Times.<\/p>\n

\n<\/div>\n
\n
\n

Thank you for your patience while we verify access.<\/p>\n

Already a subscriber?\u00a0Log in<\/a>.<\/p>\n

Want all of The Times?\u00a0Subscribe<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

The British drug maker plans to invest $50 billion in the United States as it seeks to appease President Trump.The British-Swedish drugmaker AstraZeneca has promised to invest $50 billion in the United States by 2030, the latest in a string of pledges by pharmaceutical companies as they try to fend off President Trump\u2019s threat to impose a 200 percent tariff on imported drugs.Pascal Soriot, the chief executive of AstraZeneca, announced the plans on Monday in Washington while seated next to Kevin Hassett, the director of the U.S. National Economic Council, and Glenn Youngkin, the governor of Virginia, where the company will direct a major plank of the investment.The plans \u201cunderpins our belief in America\u2019s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally,\u201d Mr. Soriot said.The investment will go to projects like building a manufacturing plant in Virginia to make drug substances, including for the company\u2019s weight loss drugs. The plant in Virginia will be AstraZeneca\u2019s largest single manufacturing investment in its 26-year history, the company said. The money will also go toward plants in California, Indiana, Maryland and Texas, as well as expanding research and development facilities in Maryland and Massachusetts.\u201cFor decades, Americans have been reliant on foreign supply of key pharmaceutical products,\u201d Howard Lutnick, the U.S. commerce secretary, said in a statement as part of the AstraZeneca announcement. \u201cPresident Trump and our nation\u2019s new tariff policies are focused on ending this structural weakness.\u201dThis year, some of the world\u2019s largest pharmaceutical companies have announced billions in investments in the United States. Roche, the Swiss company, said in April it would put $50 billion into research and development centers and manufacturing sites. Novartis, another Swiss firm, said it would invest $23 billion over the next five years. American companies including Johnson & Johnson, Eli Lilly and AbbVie have also announced major investments.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into\u00a0your Times account, or\u00a0subscribe\u00a0for all of The Times.Thank you for your patience while we verify access.Already a subscriber?\u00a0Log in.Want all of The Times?\u00a0Subscribe.<\/p>\n","protected":false},"author":1,"featured_media":32318,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-32316","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/32316","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32316"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/32316\/revisions"}],"predecessor-version":[{"id":32319,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/32316\/revisions\/32319"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/32318"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32316"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32316"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}